Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint
نویسندگان
چکیده
1 Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium 2 Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium 3 Department Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden 4 Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands 5 University of Antwerp, Antwerp, Belgium 6 Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia 7 QUAMED, Institute of Tropical Medicine, Antwerp, Belgium 8 Public Health Department, Institute of Tropical Medicine, Antwerp, Belgium 9 INSERM U 1058, Montpellier, France 10 Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Mahosot Hospital, Vientiane, Lao PDR 11 Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, Oxford University, Oxford, UK 12 Worldwide Antimalarial Resistance Network, Churchill Hospital, Oxford University, Oxford, UK 13 London School of Hygiene and Tropical Medicine, London, UK
منابع مشابه
“Sell an Ox” - The Price of Cure for Hepatitis C in Two Countries
Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household ass...
متن کاملUniversal Health Coverage in Iran: A Review of Strengths, Weaknesses, Opportunities, and Threats
Background: Universal health coverage (UHC) aims to provide access to basic health services with no financial constraints. In Iran, the major challenges to the implementation of the UHC plan include aggregation and augmentation of resources, something which could threaten the dimension of population coverage and health service delivery. Therefore, this study reviews the strengths and weaknesses...
متن کاملSubmission from : Section 2: Contribution
Much of the current debate on health care goals, medical innovation and trade rules focuses on the misalignment between the need to provide incentives to innovation – mainly through a tight intellectual property (IPR) regime – and the resulting negative consequences in terms of access to medicines. While this clash is certainly crucial, this contribution focuses on a different aspect of the mis...
متن کاملWho Updates Essential Medicines List with New Advice on Use of Antibiotics, and Adds Medicines for Hepatitis C, Hiv, Tuberculosis and Cancer
The updated list adds 30 medicines for adults and 25 for children, and specifies new uses for 9 already-listed products, bringing the total to 433 drugs deemed essential for addressing the most important public health needs. The WHO Essential Medicines List (EML) is used by many countries to increase access to medicines and guide decisions about which products they ensure are available for thei...
متن کاملCountry Pharmaceutical Situation on Access, Quality, and Rational Use of Medicines: An Evidence from a middle-income country
Introduction: Evaluation of pharmaceutical systems performance is an essential prerequisite for promoting evidence-based policy-making, improvement in health system performance. This study attempts to evaluate the performance of Iran pharmaceutical system based on the world health organization (WHO)'s indicators, including access, quality, and rational use of medicines. Methods: In this c...
متن کامل